Disclosure of a received transparency notification in accordance with article 14 of the act of 2 May 2007 on disclosure of large shareholdings

Liège, Belgium – 3 November 2026 – 22:30 CET – Regulated information – In accordance with article 14 of the Act of 2 May 2007 on disclosure of large shareholdings, **Hyloris Pharmaceuticals SA ("Hyloris") (Euronext Brussels: HYL**), the specialty pharma group committed to addressing unmet medical needs through reinventing existing medicines and smart NCE developments, today announces that it has received the following transparency notification:

1. Summary of the notification

On October 29, 2026, Hyloris received a transparency notification dated October 28, 2026, indicating that Nick Reunbrouck, following a transfer of shares on October 26, 2026, now holds 4.89% of the voting rights in Hyloris. He has thus crossed the threshold of 5% downwards.

2. Summary of the notification

The information contained in the notification is the following:

Reason for the notification:	Acquisition or disposal of voting securities or voting rights
Notification by:	A person that notifies alone
Persons subject to the notification requirement:	Nick Reunbrouck
Date on which the threshold is crossed:	October 26, 2026
Threshold that is crossed (in %):	5
Denominator:	28,000,374

Notified details:

A) Voting rights	***Previous notification***	***After the transaction***			
	# of voting rights	***# of voting rights***		***% of voting rights***	
Holders of voting rights		*Linked to securities*	*Not linked to the securities*	*Linked to securities*	*Not linked to the securities*
Nick Reunbrouck	*1,610,184*	*1,368,550*		*4.89%*	
	TOTAL	***1,368,550***	***0***	***4.89%***	***0.00%***

B) Equivalent financial instruments	***After the transaction***					
Holders of equivalent financial instruments	***Type of financial instrument***	***Expiration date***	***Exercise period or date***	***# of voting rights that may be acquired if the instrument is exercised***	***% of voting rights***	***Settlement***
-	-	-	-	*0*	*0.00%*	-
	TOTAL	-	-	*0*	*0.00%*	-

TOTAL (A & B)				***# of voting rights***	***% of voting rights***
				1,368,550	***4.89%***

About Hyloris Pharmaceuticals

Hyloris is a specialty pharma group focused on reinventing and optimizing existing medications through reformulation and repurposing to address important healthcare needs and deliver meaningful improvements for patients, healthcare

professionals, and payers. The Company's development strategy primarily focuses on leveraging established regulatory pathways, such as the FDA's 505(b)(2) pathway in the U.S., or equivalent regulatory frameworks in other regions, which are specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This approach can reduce the clinical and regulatory burden required for market entry, and significantly shorten development timelines, leading to reduced costs and risks. Hyloris has announced a broad development portfolio including more than 25 value-added medicines of which two are currently in early stages of commercialization in collaboration with commercial partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. In addition to its core strategic focus, the Company has two high-barrier generic products approved and commercialized in the U.S.: Podofilox Gel and Tranexamic Acid RTU. Beyond its announced portfolio, Hyloris has initiated several additional internal early-stage development activities, bringing the total pipeline to more than 30 products and product candidates, and continues to evaluate further product opportunities to support future growth. ***Where others stop, Hyloris starts and adds value through Reinventing Existing Medicines for unmet patient needs worldwide***. Hyloris is based in Liège, Belgium and since 2020 listed on Euronext Brussels (XBR: HYL) with about 54 people across 13 nationalities, targeting time-to-market of 7 years at an average cost of EUR 7 million per product (non-inflation adjusted).

For more information, visit www.hyloris.com and follow-us on LinkedIn.

Contacts Hyloris Pharmaceuticals :

Ann De Jaeger, CLO
legal representative of Impact WITH Empathy BV
Ann.dejaeger@hyloris.com
32 (0)475 20 13 44 - 32 (0)4 346 02 07

Stijn Van Rompay, CEO
legal representative of SVR Management BV
stijn.vanrompay@hyloris.com
32 (0)4 346 02 07

Christophe Maréchal, CFO
legal representative of CMM&C srl
Christophe.Marechal@hyloris.com
32 (0)4 346 02 07

Disclaimer and forward-looking statements

Hyloris means "high yield, lower risk", which relates to the 505(b)(2) regulatory pathway for product approval on which the Company focuses, but in no way relates or applies to an investment in the Shares. Certain statements in this press release are "forward-looking statements." These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company's control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.